Novo Nordisk shares tumble after drug trial falls short Markets Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff. The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 257.23 Danish Krone on Monday morning after trials of its new obesity shot, [...]
Exclusive: NHS must keep medicine clawback down or lose investment, says weight-jab boss Retail The NHS must keep its medicines clawback tax low and predictable or else risk disrupting the rollout of weight-loss drugs in the UK, Novo Nordisk’s UK chief has said. Sebnem Avsar Tuna, general manager of UK operations for the Ozempic and Wegovy maker, told City PM the Government must keep in place the current ceiling [...]
Mounjaro sales help almost double Ely Lilly’s UK turnover The sale of weight loss drug Mounjaro has boosted the UK turnover of pharmaceuticals giant Eli Lilly by 90 per cent during its latest financial year, it has been revealed. The division of the US group has posted a turnover of £889m for 2024, according to new accounts filed with Companies House. The new total [...]
Ozempic sales surge as priced-out Mounjaro patients seek cheaper alternative August 18, 2025 Ozempic sales have risen five-fold after a 126 per cent rise in the price of the Mounjaro drug due to pressure from US President Donald Trump. Mounjaro, manufactured by U.S. pharma giant Eli Lilly, has been the UK’s most popular weight loss jab, prescribed to an estimated 90 per cent of the country’s patients. But around [...]
Eli Lilly: UK must improve its offering as a ‘small market’ after Brexit October 14, 2024 The UK has become a “relatively small market” since leaving the European Union and must develop a different investment proposition from its counterparts in order to be interesting to multinational corporations, the boss of one of the world’s largest pharmaceuticals firms has said. Speaking shortly after his firm announced it “anticipates making £279m investment over [...]
British Patient Capital invests £90m London biotech company July 8, 2024 British Patient Capital recently also invested £10m into biotech firm Curve Therapeutics to support its cancer drug discovery technology.
